InfuSystem Holdings: Riding On The Oncology Market Opportunity

2025-11-10 01:31:35 ET

Introduction and Investment Thesis

I am bullish on InfuSystem Holdings (INFU), following an oncology contract win in the Patient Services segment. This segment saw revenue surge from $21.5 million to $22.4 million, representing an 8% YoY increase in Q3'2025. The focus here is that the additional treatment volume and third-party payer collections from Oncology and Wound Care primarily drove this increase. Even deeper, Oncology saw a 3.6% revenue increase, and Wound Care saw a 115% increase. Now, this contract win indicates that this segment has a high-growth potential. Also, a new supplier relationship in the quarter drove a significant increase in Wound Care revenue, an alternative source of revenue....

Read the full article on Seeking Alpha

For further details see: